Product image of Kelatine (D-Penicillamine) supplied by GNH India

Kelatine

Active Ingredient:
D-Penicillamine
Origin:
EU

Kelatine (D-Penicillamine)

D-Penicillamine, the active ingredient in Kelatine, is a chelating agent presented as an oral tablet for oral use. It binds excess copper and other heavy metals, facilitating their excretion, and is employed in the management of Wilson disease, cystinuria, and rheumatoid arthritis in appropriate patients. The drug is prescribed by qualified healthcare professionals and requires monitoring of laboratory parameters, and it is indicated for patients with confirmed diagnoses as part of a comprehensive therapeutic regimen.

GNH India supplies Kelatine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Manufacturer / TM Owner

Laboratório Medinfar - Produtos Farmacêuticos, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

D-Penicillamine acts as a heavy‑metal chelator and is used in several metabolic and inflammatory disorders.

  • Wilson disease: reduces copper accumulation and helps prevent hepatic and neurological damage.
  • Cystinuria: decreases urinary cystine stone formation by forming soluble complexes.
  • Rheumatoid arthritis: lowers inflammatory activity by chelating metal ions involved in oxidative processes.

How It Works

  • D-Penicillamine chelates divalent metal ions such as copper, lead, and iron by forming stable, water‑soluble complexes that are eliminated in the urine. It also reduces disulfide bonds in proteins, altering their structure and function, which contributes to its therapeutic effects in metal‑overload conditions and certain autoimmune diseases.

Side Effects

Adverse reactions to D-Penicillamine can vary from mild to severe.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Vomiting: occasional episodes, especially at treatment initiation.
  • Loss of appetite: reduced desire to eat.
  • Metallic taste: persistent metallic sensation in the mouth.
  • Rash: mild skin irritation or itching.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Agranulocytosis: severe drop in white blood cells.
  • Aplastic anemia: bone‑marrow failure leading to pancytopenia.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Liver toxicity: elevated transaminases or hepatitis.
  • Kidney dysfunction: impaired renal function or interstitial nephritis.
  • Unexplained fever: may indicate systemic reaction.

Precautions & Warnings

Safety considerations for D-Penicillamine include regular monitoring and patient education.

  • Monitor blood counts: perform regular CBC to detect cytopenias.
  • Assess liver function: periodic LFTs are recommended.
  • Check renal function: monitor serum creatinine and electrolytes.
  • Avoid in patients with known hypersensitivity: discontinue if rash or angioedema occurs.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

D-Penicillamine may interact with several medicines, requiring caution.

Major Interactions (Avoid)

  • Zinc supplements: reduce absorption of D-Penicillamine.
  • Iron preparations: chelate iron, decreasing its bioavailability.
  • Methotrexate: increased risk of toxicity.
  • Tetracycline antibiotics: may form complexes, reducing efficacy.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor blood pressure for additive hypotensive effect.
  • NSAIDs: may increase risk of renal impairment when combined.

Frequently Asked Questions

Kalatine contains D‑Penicillamine, a chelating agent prescribed for conditions such as Wilson disease, cystinuria, and rheumatoid arthritis. It works by binding excess copper and other heavy metals, facilitating their removal from the body, and by modulating inflammatory processes in arthritis.

D‑Penicillamine chelates divalent metal ions, forming stable, water‑soluble complexes that are excreted in the urine. It also reduces disulfide bonds in proteins, which can alter immune and inflammatory pathways, contributing to its therapeutic effects in metal‑overload disorders and certain autoimmune diseases.

The dosage of Kelatine is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and laboratory monitoring. Only a qualified healthcare professional can determine the appropriate dose and schedule for each patient.

Safety of D‑Penicillamine in pregnancy and lactation has not been fully established. It should be used only if the potential benefits justify the possible risks to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Kelatine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Kalatine (D‑Penicillamine) is a small‑molecule chelator with a broad metal‑binding profile, whereas alternatives like trientine or dimercaprol have different affinity spectra and side‑effect profiles. Choice of agent depends on the specific metal overload, patient tolerance, and clinical judgment.

Kalatine tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Kalatine is taken orally, usually with a full glass of water. It is often recommended to take the medication on an empty stomach, at least one hour before or two hours after meals, unless the prescriber advises otherwise.

Serious risks include agranulocytosis, aplastic anemia, severe skin reactions such as Stevens‑Johnson syndrome, liver toxicity, and renal impairment. Patients should be monitored regularly for blood counts, liver and kidney function, and any signs of severe adverse reactions.

Kalatine should not be used by individuals with known hypersensitivity to D‑Penicillamine, those with active severe liver disease, or patients with existing severe bone‑marrow suppression. Contraindications may also include certain metabolic disorders, and the prescriber should evaluate each case.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.